It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Precise, scalable, and quantitative evaluation of whole slide images is crucial in neuropathology. We release a deep learning model for rapid object detection and precise information on the identification, locality, and counts of cored plaques and cerebral amyloid angiopathy (CAA). We trained this object detector using a repurposed image-tile dataset without any human-drawn bounding boxes. We evaluated the detector on a new manually-annotated dataset of whole slide images (WSIs) from three institutions, four staining procedures, and four human experts. The detector matched the cohort of neuropathology experts, achieving 0.64 (model) vs. 0.64 (cohort) average precision (AP) for cored plaques and 0.75 vs. 0.51 AP for CAAs at a 0.5 IOU threshold. It provided count and locality predictions that approximately correlated with gold-standard human CERAD-like WSI scoring (p = 0.07 ± 0.10). The openly-available model can quickly score WSIs in minutes without a GPU on a standard workstation.
A deep learning model rapidly identifies locality and counts of cored plaques and cerebral amyloid angiopathy in whole slide images comparably to human experts and without a GPU on a standard workstation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 University of California, San Francisco, Institute for Neurodegenerative Diseases, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, Bakar Computational Health Sciences Institute, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, San Francisco, Department of Pharmaceutical Chemistry, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, San Francisco, Department of Bioengineering and Therapeutic Sciences, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, San Francisco, Kavli Institute for Fundamental Neuroscience, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
2 University of California, Los Angeles, Department of Pathology and Laboratory Medicine, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718)
3 University of California, Los Angeles, Department of Pathology and Laboratory Medicine, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718); David Geffen School of Medicine at University of California, Los Angeles, Department of Neurology, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718)
4 University of California, Department of Pathology & Laboratory Medicine, Irvine, USA (GRID:grid.266093.8) (ISNI:0000 0001 0668 7243)
5 University of California-Davis, Department of Neurology, School of Medicine, Davis, USA (GRID:grid.27860.3b) (ISNI:0000 0004 1936 9684)
6 University of California, Davis, Department of Pathology and Laboratory Medicine, School of Medicine, Sacramento, USA (GRID:grid.27860.3b) (ISNI:0000 0004 1936 9684)